Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart + anlotinib maintenance versus tislelizumab maintenance with platinum-etoposide first-line treatment for extensive-stage small cell lung cancer
CTR20250323Phase 2Terminated
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Feb 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart, anlotinib, tislelizumab, etoposide, carboplatin in small cell lung cancer (SCLC), sponsored by Nanjing Shunxin Pharmaceutical. Started Feb 2025; status: terminated.
02
Drugs
benmelstobartanlotinibtislelizumabetoposidecarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20250323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250323.